Piramal Pharma Q2 Results Review: Key Takeaways for Investors
Motilal Oswal has maintained its ‘Buy’ rating on Piramal Pharma Ltd. despite the company facing near-term headwinds. In this article, we will delve into the key takeaways from the Q2 results and analyze the factors that are expected to impact the company’s performance in the coming quarters.
Q2 Results: A Mixed Bag
Piramal Pharma’s Q2 results were a mixed bag, with the company reporting a revenue growth of 10% year-on-year (YoY). However, the Ebitda margins were impacted due to higher operational costs and supply challenges in the CHG segment.
Near-Term Headwinds: A Gradual Scale-Up of CDMO Business
One of the major near-term headwinds facing Piramal Pharma is the gradual scale-up of its CDMO (Contract Development and Manufacturing Organization) business. The company has been investing heavily in this segment, and the ramp-up is expected to take some time. However, once the scale-up is complete, the CDMO business is expected to be a major growth driver for the company.
Supply Challenges in the CHG Segment
Piramal Pharma is also facing supply challenges in the CHG (Chlorhexidine Gluconate) segment. The company is working to resolve these issues, but they are expected to impact the company’s performance in the near term.
Higher Operational Costs
Piramal Pharma’s operational costs have increased due to various factors, including higher raw material costs and increased spending on research and development. The company is working to optimize its costs and improve its efficiency, but the higher operational costs are expected to impact the company’s margins in the near term.
Motilal Oswal’s ‘Buy’ Rating: What Does it Mean for Investors?
Motilal Oswal’s decision to maintain its ‘Buy’ rating on Piramal Pharma despite the near-term headwinds is a positive sign for investors. The brokerage firm believes that the company’s long-term growth prospects are intact and that the near-term challenges are temporary.
Investment Thesis
Motilal Oswal’s investment thesis on Piramal Pharma is based on the company’s strong growth prospects in the CDMO segment, its improving return on equity, and its attractive valuations. The brokerage firm believes that the company’s stock is undervalued and that it has the potential to deliver strong returns to investors in the long term.
Conclusion
In conclusion, Piramal Pharma’s Q2 results were a mixed bag, with the company facing near-term headwinds due to a gradual scale-up of its CDMO business, supply challenges in the CHG segment, and higher operational costs. However, Motilal Oswal’s decision to maintain its ‘Buy’ rating on the stock is a positive sign for investors. The brokerage firm believes that the company’s long-term growth prospects are intact and that the near-term challenges are temporary. Investors who are looking to invest in the Indian pharma sector may want to consider Piramal Pharma as a potential investment opportunity.